The COX-2 specific inhibitor, valdecoxib, is an effective, opioid-sparing analgesic in patients undergoing total knee arthroplasty

Journal of Pain and Symptom Management

Volumn 25, Issue 2, 2003, Pages 133-141

  Reynolds, Lowell W ^a   Hoo, Robert K ^a   Brill, Robert J ^b   North, Janine ^c   Recker, David P ^c   Verburg, Kenneth M ^a,c  

^a LOMA LINDA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Renstar Medical Research   (United States)

^c PFIZER INC   (United States)

Author keywords

Analgesia; COX 2 specific inhibitor; Knee arthroplasty; Opioid sparing; Post operative pain; Valdecoxib

Indexed keywords

ACETYLSALICYLIC ACID; MIDAZOLAM; MORPHINE; PLACEBO; VALDECOXIB;

ABDOMINAL DISEASE; ADULT; AGED; ANEMIA; ANOREXIA; ANXIETY DISORDER; ARTICLE; CLINICAL TRIAL; CONFUSION; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; DYSPEPSIA; DYSPNEA; FEMALE; FEVER; HEADACHE; HUMAN; INSOMNIA; MALE; MULTICENTER STUDY; NAUSEA; OLIGURIA; PAIN ASSESSMENT; PATIENT CONTROLLED ANALGESIA; POSTOPERATIVE PAIN; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SOMNOLENCE; TOTAL KNEE REPLACEMENT; URINE RETENTION; VERTIGO; VOMITING;

AGED; AGED, 80 AND OVER; ANALGESICS, OPIOID; ARTHROPLASTY, REPLACEMENT, KNEE; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; ISOENZYMES; ISOXAZOLES; MALE; MEMBRANE PROTEINS; MIDDLE AGED; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; SULFONAMIDES;

EID: 0037318024     PISSN: 08853924     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0885-3924(02)00637-1     Document Type: Article

References (27)

1. Nussenzveig T. Pain management after total joint replacement and its impact on patient outcomes. AORN J. 70:1999;1060-1062.
2. Capdevilla X., Barthelet Y., Biboulet P.et al. Effects of perioperative analgesic technique on the surgical outcome and duration of rehabilitation after major knee surgery. Anesthesiology. 91:1999;8-15.
3. Kehlet H., Rung G.W., Callesen T. Postoperative opioid analgesia. time for a reconsideration? J Clin Anesth. 8:1996;441-445.
4. Shaieb M., Watson B., Atkinson R. Bleeding complications with enoxaparin for deep venous thrombosis prophylaxis. J Arthroplast. 14:1999;432-438.
5. Borda I.T., Koff R. NSAIDs. a profile of adverse effects:1995;Hanley and Belfus, Inc, Philadelphia.
6. Garcia Rodriguez L.A., Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual nonsteroidal anti-inflammatory drugs. Lancet. 343:1994;769-772.
7. Langman M.J., Weil J., Wainwright P.et al. Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet. 343:1994;1075-1078.
8. Schlondorff D. Renal complications of nonsteroidal anti-inflammatory drugs. Kidney Int. 44:1993;643-653.
9. Talley J.J., Brown D.L., Carter J.S.et al. 4-5-Methyl-3-phenylisoxazol-4-yl-benzenesulfonamide, valdecoxib. a potent and selective inhibitor of COX-2 J Med Chem. 43:2000;775-777.
10. Leese P., Talwalker S., Recker D. Valdecoxib, a novel COX-2 specific inhibitor, does not impair platelet function in healthy adults. results of a randomized controlled trial Am J Emerg Med. 20:2002;275-281.
11. Leese P, Recker D, Kuss M. A double-blind, placebo-controlled study to evaluate the effects of valdecoxib, a novel COX-2 specific inhibitor, on platelet function in the elderly. European League Against Rheumatism, Prague 13-16 June: 2001.
12. Sikes D., Agrawal N., Zhao W.W.et al. Incidence of gastroduodenal ulcers associated with valdecoxib compared with that of ibuprofen and diclofenac in patients with OA. Eur J Gastroenterol Hepatol. 14:2002;1101-1111.
13. Camu F., Beecher T., Recker D.et al. Valdecoxib, a COX-2 specific inhibitor, is an efficacious, opioid-sparing analgesic in patients undergoing hip arthroplasty. Am J Ther. 9:2001;43-51.
14. Woolf C.J., Desjardins P.J., Talwalker S.et al. The COX-2 specific inhibtor, valdecoxib, administered preoperatively, provides effective and long lasting relief from acute post-operative pain. results from two randomized controlled trials Anesthesiology. 97:2002;565-573.
15. Desjardins P., Daniels S., Talwalker S.et al. Single oral doses of valdecoxib are as effective as oxycodone/acetaminophen in reducing pain following oral surgery. results of two randomized, double-blind trials JADA. 133:2002;611-621.
16. Delbos A., Boccard E. The morphine-sparing effect of propacetamol in orthopedic postoperative pain. J Pain Symptom Manage. 10:1995;279-286.
17. Miller R. Survival Analyses. 1998;John Wiley & Sons, Inc, New York.
18. Simon R., Lee Y.J. Nonparametric confidence limits for survival probabilities and median survival time. Cancer Treat Rep. 66:1982;37-42.
19. Bunemann L., Thorshauge H., Herlevsen P.et al. Analgesia for outpatient surgery. placebo versus naproxen sodium (a non-steroidal anti-inflammatory drug) given before or after surgery Eur J Anaesthesiol. 11:1994;461-464.
20. Ding Y., White P.F. Comparative effects of ketorolac, dezocine and fentanyl as adjuvants during outpatient anesthsia. Anesth Analg. 75:1992;566-571.
21. Hovorka J., Kallela H., Korttila K. Effect of intravenous diclofenac on pain and recovery profile after day-case laparoscopy. Eur J Anaesthesiol. 10:1993;105-108.
22. Rosenblum M., Weller R.S., Conrad P.L.et al. Ibuprofen provides longer lasting analgesia than fentanyl after laproscopic surgery. Anesth Analg. 73:1991;255-259.
23. Kehlet H. Acute pain control and accelerated postoperative surgical recovery. Surg Clin North Am. 79:1999;431-443.
24. Beaver W. Impact of non-narcotic oral analgesics on pain management. Am J Med. 849(suppl 5A):1988;3-15.
25. Smalley W., Ray W., Daugherty J.et al. Nonsteroidal anti-inflammatory drugs and the incidence of hospitalizations for peptic ulcer disease in elderly persons. Am J Epidemiol. 141:1995;539-545.
26. Wen S. Nephrotoxicities of nonsteroidal anti-inflammatory drugs. J Formos Med Assoc. 96:1997;157-171.
27. Karim A, Schwartz L, Boynton J, et al. Multiple-dose valdecoxib does not affect the steady-state pharmacokinetics of warfarin. American Society of Health-System Pharmacists Annual Meeting [Abstract]. Am J Health-System Pharmacy 2001;36:Abstract P-456E.